News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
411,856 Results
Type
Article (17957)
Company Profile (120)
Press Release (393778)
Multimedia
Podcasts (60)
Webinars (13)
Section
Business (135977)
Career Advice (868)
Deals (24684)
Drug Delivery (70)
Drug Development (47795)
Employer Resources (70)
FDA (8717)
Job Trends (8651)
News (221215)
Policy (18768)
Tag
Academia (696)
Accelerated approval (4)
Adcomms (9)
Allergies (51)
Alliances (31532)
ALS (59)
Alzheimer's disease (631)
Antibody-drug conjugate (ADC) (65)
Approvals (8787)
Artificial intelligence (168)
Autoimmune disease (15)
Automation (8)
Bankruptcy (212)
Best Places to Work (6157)
BIOSECURE Act (10)
Biosimilars (86)
Biotechnology (57)
Bladder cancer (36)
Brain cancer (22)
Breast cancer (144)
Cancer (1269)
Cardiovascular disease (120)
Career advice (746)
Career pathing (14)
CAR-T (71)
CDC (5)
Cell therapy (208)
Cervical cancer (8)
Clinical research (40461)
Collaboration (588)
Compensation (380)
Complete response letters (20)
COVID-19 (988)
CRISPR (39)
C-suite (277)
Cystic fibrosis (60)
Data (1456)
Denatured (16)
Depression (29)
Diabetes (145)
Diagnostics (2946)
Digital health (6)
Diversity (2)
Diversity, equity & inclusion (20)
Drug discovery (80)
Drug pricing (92)
Drug shortages (13)
Duchenne muscular dystrophy (72)
Earnings (59021)
Editorial (21)
Employer branding (13)
Employer resources (66)
Events (64156)
Executive appointments (664)
FDA (9605)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (463)
Gene editing (62)
Generative AI (11)
Gene therapy (188)
GLP-1 (462)
Government (1675)
Grass and pollen (4)
Guidances (154)
Healthcare (7488)
HIV (15)
Huntington's disease (11)
IgA nephropathy (24)
Immunology and inflammation (75)
Immuno-oncology (4)
Indications (25)
Infectious disease (1043)
Inflammatory bowel disease (77)
Inflation Reduction Act (7)
Influenza (18)
Intellectual property (76)
Interviews (109)
IPO (11093)
IRA (36)
Job creations (2747)
Job search strategy (681)
Kidney cancer (10)
Labor market (23)
Layoffs (282)
Leadership (9)
Legal (5082)
Liver cancer (36)
Longevity (7)
Lung cancer (171)
Lymphoma (99)
Machine learning (6)
Management (22)
Manufacturing (274)
MASH (64)
Medical device (4733)
Medtech (4736)
Mergers & acquisitions (14052)
Metabolic disorders (432)
Multiple sclerosis (38)
NASH (17)
Neurodegenerative disease (54)
Neuropsychiatric disorders (13)
Neuroscience (960)
NextGen: Class of 2025 (2868)
Non-profit (1192)
Now hiring (15)
Obesity (221)
Opinion (161)
Ovarian cancer (37)
Pain (83)
Pancreatic cancer (44)
Parkinson's disease (74)
Partnered (10)
Patents (172)
Patient recruitment (81)
Peanut (18)
People (41339)
Pharmaceutical (65)
Pharmacy benefit managers (14)
Phase I (11230)
Phase II (17367)
Phase III (14755)
Pipeline (1184)
Policy (116)
Postmarket research (1729)
Preclinical (4522)
Press Release (72)
Prostate cancer (83)
Psychedelics (13)
Radiopharmaceuticals (183)
Rare diseases (280)
Real estate (3793)
Recruiting (26)
Regulatory (13358)
Reports (23)
Research institute (790)
Resumes & cover letters (126)
Rett syndrome (9)
RNA editing (5)
RSV (10)
Schizophrenia (58)
Series A (83)
Series B (49)
Service/supplier (3)
Sickle cell disease (40)
Special edition (8)
Spinal muscular atrophy (116)
Sponsored (13)
Startups (2228)
State (2)
Stomach cancer (5)
Supply chain (42)
Tariffs (53)
The Weekly (42)
Vaccines (229)
Venture capital (28)
Weight loss (127)
Women's health (13)
Worklife (4)
Date
Today (53)
Last 7 days (288)
Last 30 days (987)
Last 365 days (16970)
2025 (9919)
2024 (19566)
2023 (22809)
2022 (31096)
2021 (32578)
2020 (30638)
2019 (23683)
2018 (18364)
2017 (19761)
2016 (18575)
2015 (22496)
2014 (18492)
2013 (15579)
2012 (16767)
2011 (17457)
2010 (16480)
Location
Africa (443)
Alabama (29)
Alaska (3)
Arizona (98)
Arkansas (4)
Asia (26760)
Australia (3555)
California (3895)
Canada (1516)
China (411)
Colorado (177)
Connecticut (172)
Delaware (109)
Europe (54443)
Florida (681)
Georgia (78)
Hawaii (1)
Idaho (28)
Illinois (336)
India (20)
Indiana (211)
Iowa (8)
Japan (183)
Kansas (76)
Kentucky (24)
Louisiana (8)
Maine (45)
Maryland (461)
Massachusetts (3199)
Michigan (114)
Minnesota (224)
Mississippi (2)
Missouri (44)
Montana (17)
Nebraska (13)
Nevada (40)
New Hampshire (23)
New Jersey (1395)
New Mexico (11)
New York (1063)
North Carolina (677)
North Dakota (5)
Northern California (1741)
Ohio (123)
Oklahoma (6)
Oregon (19)
Pennsylvania (807)
Puerto Rico (11)
Rhode Island (19)
South America (671)
South Carolina (15)
Southern California (1521)
Tennessee (80)
Texas (549)
United States (15030)
Utah (95)
Virginia (152)
Washington D.C. (42)
Washington State (300)
West Virginia (3)
Wisconsin (40)
411,856 Results for "novartis pharmaceuticals corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
I&I
Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint
The partnership with Matchpoint Therapeutics gets Novartis global rights on all molecules for several unannounced inflammatory diseases identified through the biotech’s discovery platform.
July 24, 2025
·
2 min read
·
Dan Samorodnitsky
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.
July 3, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO Vas Narasimhan told reporters that for most medicines, it typically takes three to four years to completely relocate production.
July 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
July 11, 2025
·
4 min read
Cardiovascular disease
Novartis Makes Potential $750M+ Bet Per Cardiovascular Disease Target in Another Flagship Pact
Flagship Pioneering’s ProFound Therapeutics will use its proprietary technology to mine the expanded proteome for novel cardiovascular therapeutics. Novartis has promised to pay up to $750 million per target, though it has not specified how many targets it will go after.
June 26, 2025
·
2 min read
·
Tristan Manalac
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Legal
Former Chinook Board Member Indicted for Insider Trading Related to $3.2B Novartis Buy
Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to the DOJ’s allegations, used confidential information to conduct insider trading.
May 28, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Novartis completes acquisition of Regulus Therapeutics
June 25, 2025
·
6 min read
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
1 of 41,186
Next
